---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111484"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:19:59.034448+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations

## Summary
- UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.
- Company eligible for two additional $37.5M earn-out payments.
- Recast financials for FY 2024 and 2023 show biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations.
- Recast is for incorporation into a Form S-3 registration statement filed Nov 13, 2025.
- No other events after 2024 10-K filing are reflected except discontinued ops presentation.

## SEC filing metadata
- accession: 0001104659-25-111484
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/0001104659-25-111484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111484
- JSON: https://secwatch.observer/filing/0001104659-25-111484.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.